Ancora Heart

Physicians

THE ACCUCINCH® VENTRICULAR RESTORATION SYSTEM

As the only completely transcatheter therapy to treat the enlarged left ventricle, the AccuCinch Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart.

For heart failure patients with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy, early feasibility clinical data suggests that the AccuCinch System may provide a new treatment option by filling the gap between medication or cardiac resynchronization therapy, and left ventricular assist devices (LVADs) or a heart transplant.

The AccuCinch Ventricular Restoration System has been granted Breakthrough Device Designation by the FDA

CAUTION – Investigational device.  Limited by United States law to investigational use.

ACCUCINCH SYSTEM GOALS

  • Reduce the size of the left ventricle and reduce wall stress
  • Provide support and strength to the left ventricle
  • Initiate a biological process of reverse remodeling to improve myocardial contractility and overall cardiac function

Improved
Quality of Life

Improved Functional Capacity

Improved Life Expectancy

HOW THE ACCUCINCH SYSTEM WORKS

ACCESS

  • The left ventricle (LV) is accessed through the aortic valve using the AccuCinch Guide catheter
  • A guide wire is then placed within the LV, behind the chordae, using the AccuCinch NavCath

DELIVERY

  • The AccuCinch TracCath is advanced over the guide wire to provide a template for implant delivery
  • During AccuCinch Implant delivery, a series of anchors, each separated by a spacer to distribute force, are delivered over a cable are placed into the LV wall

CINCH

  • The AccuCinch Implant is then cinched and secured with a nitinol lock to reduce the size of the LV

PROMISING FINDINGS TO DATE

Early feasibility clinical data has demonstrated that the AccuCinch System may improve quality of life, improve functional capacity, and enable reverse remodeling in symptomatic heart failure patients with reduced ejection fraction (HFrEF). J Cardiac Fail 2023;29:1046-1055

READ JCF PUBLICATION HERE

Watch Dr. Nadira Hamid, Interventional Echocardiographer, Cardiologist at Allina Health Minneapolis Heart Institute and Assistant Director of the Echocardiographic Core Lab at CRF, present “Transcatheter Left Ventricular Restoration in Patients with Heart Failure” at the Technology and Heart Failure Therapeutics Conference

THT 2023 – Boston, MA

THE CORCINCH-HF STUDY

Patients are currently being enrolled in The CORCINCH-HF Study, a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation.

LEARN ABOUT CORCINCH-HF
FOOTNOTES

1 Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
2 Koelling T, et al. American Heart Journal. Volume 144, Issue 3, Sep 2002, Pages 524-529. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction.

To Learn More

GET IN TOUCH